Larry L. Wood - 03 May 2024 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
Global President TAVR & Surg
Signature
Linda J. Park, Attorney-in-Fact
Issuer symbol
EW
Transactions as of
03 May 2024
Net transactions value
-$335,469
Form type
4
Filing time
06 May 2024, 19:17:58 UTC
Previous filing
19 Apr 2024
Next filing
09 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Tax liability $33,599 -395 -0.18% $85.06 213,347 03 May 2024 Direct
transaction EW Common Stock Options Exercise $0 +6,675 +3.1% $0.000000 220,022 04 May 2024 Direct F1
transaction EW Common Stock Tax liability $301,870 -3,541 -1.6% $85.25 216,481 04 May 2024 Direct
holding EW Common Stock 496 03 May 2024 401(k)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Performance Rights Options Exercise $0 -6,675 -100% $0.000000* 0 04 May 2024 Common Stock 6,675 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This Form 4 includes quarterly acquisition of shares under the Issuer's Employee Stock Purchase Plan.